Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation.

ABSTRACT:

Background

Lenvatinib (LEN) has shown great efficacy but important toxicity in patients with advanced radioactive iodine-refractory (RAI-R) thyroid cancer (TC); a focused evaluation of its impact on patients' quality of life (QoL) is still lacking. Our prospective study investigated the impact of this drug on QoL in a group of RAI-R TC patients treated at our centre.

Methods

All patients filled in two questionnaires before and during treatment: (1) the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events adapted questionnaire, assessing prevalence, severity, and/or interference on daily activities of the most frequent symptomatic adverse events (AEs) reported in previous clinical trials during therapy with LEN, and (2) the European Quality

SUBMITTER: Nervo A 

PROVIDER: S-EPMC7983562 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature